臺灣學術機構典藏系統 (Taiwan Academic Institutional Repository, TAIR)

關於TAIR
	計畫說明

瀏覽
	典藏機構
	作者
	題名
	日期
	統計圖表
	機構即時統計
	學術趨勢

消息
	2019臺灣學術機構典藏研討會
	機構典藏系統RC7版本已發佈

著作權
	出版社及期刊政策查詢
	TAIR著作權會議記錄

相關連結
	機構典藏計畫網站
	ROAR
	OpenDOAR
	SHERPA
	OAIster
	JAIRO
	Ira
	DSPACE
	RWWR
	臺大學術典藏NTU Scholars

"yang c h"的相關文件

回到依作者瀏覽
依題名排序	依日期排序

顯示項目 581-605 / 1273 (共51頁)
<< < 19 20 21 22 23 24 25 26 27 28 > >>
每頁顯示[10|25|50]項目

機構	日期	題名	作者
臺大學術典藏	2020-12-02T02:35:51Z	Quality of life of lung cancer patients: Validation of the Taiwan Chinese version of the EORTC QLQ-C30 and QLQ-LC13	Chie W.-C.;Yang C.-H.;Hsu C.;Pan-Chyr Yang; Chie W.-C.; Yang C.-H.; Hsu C.; PAN-CHYR YANG
臺大學術典藏	2020-12-02T02:35:46Z	Survival of stage IIIB/IV non-small cell lung cancer patients who received chemotherapy but did not participate in clinical trials	Kuo S.-H.;Yang C.-H.;Yu C.-J.;Hsu C.;Cheng A.-L.;Pan-Chyr Yang; Kuo S.-H.; Yang C.-H.; Yu C.-J.; Hsu C.; Cheng A.-L.; PAN-CHYR YANG
臺大學術典藏	2020-12-02T02:35:41Z	Gefitinib reverses chemotherapy resistance in gefitinib-insensitive multidrug resistant cancer cells expressing ATP-binding cassette family protein	Yang C.-H.;Huang C.-J.;Yang C.-S.;Chu Y.-C.;Cheng A.-L.;Whang-Peng J.;Pan-Chyr Yang; Yang C.-H.; Huang C.-J.; Yang C.-S.; Chu Y.-C.; Cheng A.-L.; Whang-Peng J.; PAN-CHYR YANG
臺大學術典藏	2020-12-02T02:35:41Z	Survival outcome of inoperable non-small cell lung cancer patients receiving conventional dose epirubicin and paclitaxel as first-line treatment	PAN-CHYR YANG; Yang C.-H.;Chen M.-C.;Cheng A.-L.;Hsu C.-H.;Yeh K.-H.;Yu Y.-C.;Whang-Peng J.;Pan-Chyr Yang; Yang C.-H.; Chen M.-C.; Cheng A.-L.; Hsu C.-H.; Yeh K.-H.; Yu Y.-C.; Whang-Peng J.
臺大學術典藏	2020-12-02T02:35:37Z	Gefitinib treatment for non-small cell lung cancer - A study including patients with poor performance status	Su W.-P.;Yang C.-H.;Yu C.-J.;Shih J.-Y.;Hsu C.;Pan-Chyr Yang; Su W.-P.; Yang C.-H.; Yu C.-J.; Shih J.-Y.; Hsu C.; PAN-CHYR YANG
臺大學術典藏	2020-12-02T02:35:33Z	Epidermal growth factor receptor mutations in needle biopsy/aspiration samples predict response to gefitinib therapy and survival of patients with advanced nonsmall cell lung cancer	Shih J.-Y.;Gow C.-H.;Yu C.-J.;Yang C.-H.;Chang Y.-L.;Tsai M.-F.;Hsu Y.-C.;Chen K.-Y.;Su W.-P.;Pan-Chyr Yang; Shih J.-Y.; Gow C.-H.; Yu C.-J.; Yang C.-H.; Chang Y.-L.; Tsai M.-F.; Hsu Y.-C.; Chen K.-Y.; Su W.-P.; PAN-CHYR YANG
臺大學術典藏	2020-12-02T02:34:52Z	Predictive factors of gefitinib antitumor activity in East Asian advanced non-small cell lung cancer patients	Chang G.-C.; Tsai C.-M.; Chen K.-C.; Yu C.-J.; Shih J.-Y.; Yang T.-Y.; Lin C.-P.; Hsu J.-Y.; Chiu C.-H.; Perng R.-P.; Pan-Chyr Yang; Yang C.-H.; Chang G.-C.; PAN-CHYR YANG et al.
臺大學術典藏	2020-12-02T02:34:49Z	Survival outcome and predictors of gefitinib antitumor activity in East Asian chemonaive patients with advanced nonsmall cell lung cancer	Yang C.-H.; Shih J.-Y.; Chen K.-C.; Yu C.-J.; Yang T.-Y.; Lin C.-P.; Su W.-P.; Gow C.-H.; Hsu C.; Chang G.-C.; Pan-Chyr Yang; Yang C.-H.; PAN-CHYR YANG et al.
臺大學術典藏	2020-12-02T02:34:44Z	A phase II study of oral vinorelbine in combination with cisplatin conducted in Taiwan in patients with unresectable localized or metastatic non-small cell lung carcinoma	Chen Y.-M.; Yu C.-J.; Yang C.-H.; Perng R.-P.; Tsai C.-M.; Shih J.-F.; Cheng A.-L.; Lefresne F.; Barbier M.; Pouget J.-C.; Pan-Chyr Yang; Chen Y.-M.; PAN-CHYR YANG et al.
臺大學術典藏	2020-12-02T02:34:40Z	Radiotherapy in lung adenocarcinoma with brain metastases: Effects of activating epidermal growth factor receptor mutations on clinical response	Gow C.-H.;Chien C.-R.;Chang Y.-L.;Chiu Y.-H.;Kuo S.-H.;Shih J.-Y.;Chang Y.-C.;Yu C.-J.;Yang C.-H.;Pan-Chyr Yang; Gow C.-H.; Chien C.-R.; Chang Y.-L.; Chiu Y.-H.; Kuo S.-H.; Shih J.-Y.; Chang Y.-C.; Yu C.-J.; Yang C.-H.; PAN-CHYR YANG
臺大學術典藏	2020-12-02T02:34:40Z	MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib	Bean J.; Brennan C.; Shih J.-Y.; Riely G.; Viale A.; Wang L.; Chitale D.; Motoi N.; Szoke J.; Broderick S.; Balak M.; Chang W.-C.; Yu C.-J.; Gazdar A.; Pass H.; Rusch V.; Gerald W.; Huang S.-F.; Pan-Chyr Yang; Miller V.; Ladanyi M.; Yang C.-H.; Pao W.; Bean J.; PAN-CHYR YANG et al.
臺大學術典藏	2020-12-02T02:34:39Z	Caveolin-1 expression is significantly associated with drug resistance and poor prognosis in advanced non-small cell lung cancer patients treated with gemcitabine-based chemotherapy	Ho C.-C.;Kuo S.-H.;Huang P.-H.;Huang H.-Y.;Yang C.-H.;Pan-Chyr Yang; Ho C.-C.; Kuo S.-H.; Huang P.-H.; Huang H.-Y.; Yang C.-H.; PAN-CHYR YANG
臺大學術典藏	2020-12-02T02:34:36Z	Outcome of advanced nonsmall cell lung cancer patients receiving gemcitabine and weekly paclitaxel as first-line treatment	Lin Z.-Z.; Hsu C.; Chang Y.-C.; Yu C.-J.; Hsu C.-H.; Lin C.-C.; Cheng A.-L.; PAN-CHYR YANG; Yang C.-H.
臺大學術典藏	2020-12-02T02:34:34Z	Lung cancer with epidermal growth factor receptor exon 20 mutations is associated with poor gefitinib treatment response	Wu J.-Y.;Wu S.-G.;Yang C.-H.;Gow C.-H.;Chang Y.-L.;Yu C.-J.;Shin J.-Y.;Pan-Chyr Yang; Wu J.-Y.; Wu S.-G.; Yang C.-H.; Gow C.-H.; Chang Y.-L.; Yu C.-J.; Shin J.-Y.; PAN-CHYR YANG
臺大學術典藏	2020-12-02T02:34:33Z	Frequent epidermal growth factor receptor gene mutations in malignant pleural effusion of lung adenocarcinoma	Wu S.-G.; Gow C.-H.; Yu C.-J.; Chang Y.-L.; Yang C.-H.; Hsu Y.-C.; Shih J.-Y.; Lee Y.-C.; PAN-CHYR YANG
臺大學術典藏	2020-12-02T02:34:33Z	Specific EGFR mutations predict treatment outcome of stage IIIB/IV patients with chemotherapy-naive non-small-cell lung cancer receiving first-line gefitinib monotherapy	Yang C.-H.;Pan-Chyr Yang Et Al.; Yang C.-H.; PAN-CHYR YANG et al.
臺大學術典藏	2020-12-02T02:34:31Z	First- or second-line therapy with gefitinib produces equal survival in non-small cell lung cancer	Wu J.-Y.; Yu C.-J.; Yang C.-H.; Wu S.-G.; Chiu Y.-H.; Gow C.-H.; Chang Y.-C.; Hsu Y.-C.; Wei P.-F.; Shih J.-Y.; Pan-Chyr Yang; Wu J.-Y.; Yu C.-J.; Yang C.-H.; Wu S.-G.; Chiu Y.-H.; Gow C.-H.; Chang Y.-C.; Hsu Y.-C.; Wei P.-F.; Shih J.-Y.; PAN-CHYR YANG
臺大學術典藏	2020-12-02T02:34:30Z	Gemcitabine plus conventional-dose epirubicin versus gemcitabine plus cisplatin as first-line chemotherapy for stage IIIB/IV non-small cell lung carcinoma-A randomized phase II trial	Hsu C.; Kuo S.-H.; Hu F.-C.; Cheng A.-L.; Shih J.-Y.; Yu C.-J.; Lin C.-C.; Huang T.-C.; PAN-CHYR YANG; Yang C.-H.
臺大學術典藏	2020-12-02T02:34:29Z	Good response to gefitinib in lung adenocarcinoma of complex epidermal growth factor receptor (EGFR) mutations with the classical mutation pattern	Wu S.-G.; Chang Y.-L.; Hsu Y.-C.; Wu J.-Y.; Yang C.-H.; Yu C.-J.; Tsai M.-F.; Shih J.-Y.; Pan-Chyr Yang; Wu S.-G.; Chang Y.-L.; Hsu Y.-C.; Wu J.-Y.; Yang C.-H.; Yu C.-J.; Tsai M.-F.; Shih J.-Y.; PAN-CHYR YANG
臺大學術典藏	2020-12-02T02:34:27Z	Comparison of epidermal growth factor receptor mutations between primary and corresponding metastatic tumors in tyrosine kinase inhibitor-naive non-small-cell lung cancer	Gow C.-H.; Chang Y.-L.; Hsu Y.-C.; Tsai M.-F.; Wu C.-T.; Yu C.-J.; Yang C.-H.; Lee Y.-C.; Pan-Chyr Yang; Shih J.-Y.; Gow C.-H.; Chang Y.-L.; Hsu Y.-C.; Tsai M.-F.; Wu C.-T.; Yu C.-J.; Yang C.-H.; Lee Y.-C.; PAN-CHYR YANG; Shih J.-Y.
臺大學術典藏	2020-12-02T02:34:25Z	EGFR intron 1 dinucleotide repeat polymorphism is associated with the occurrence of skin rash with gefitinib treatment	Huang C.-L.; Yang C.-H.; Yeh K.-H.; Hu F.-C.; Chen K.-Y.; Shih J.-Y.; Lin Z.-Z.; Yu C.-J.; Cheng A.-L.; Pan-Chyr Yang; Huang C.-L.; Yang C.-H.; Yeh K.-H.; Hu F.-C.; Chen K.-Y.; Shih J.-Y.; Lin Z.-Z.; Yu C.-J.; Cheng A.-L.; PAN-CHYR YANG
臺大學術典藏	2020-12-02T02:34:20Z	Second-line treatments after first-line gefitinib therapy in advanced nonsmall cell lung cancer	Wu J.-Y.;Shih J.-Y.;Yang C.-H.;Chen K.-Y.;Ho C.-C.;Yu C.-J.;Pan-Chyr Yang; Wu J.-Y.; Shih J.-Y.; Yang C.-H.; Chen K.-Y.; Ho C.-C.; Yu C.-J.; PAN-CHYR YANG
臺大學術典藏	2020-12-02T02:34:19Z	Octogenarians with advanced non-small cell lung cancer: Treatment modalities, survival, and prognostic factors	Chen K.-Y.;Chen J.-H.;Shih J.-Y.;Yang C.-H.;Yu C.-J.;Pan-Chyr Yang; Chen K.-Y.; Chen J.-H.; Shih J.-Y.; Yang C.-H.; Yu C.-J.; PAN-CHYR YANG
臺大學術典藏	2020-12-02T02:34:18Z	Influence of first-line chemotherapy and EGFR mutations on second-line gefitinib in advanced non-small cell lung cancer	Wu J.-Y.;Yu C.-J.;Shih J.-Y.;Yang C.-H.;Pan-Chyr Yang; Wu J.-Y.; Yu C.-J.; Shih J.-Y.; Yang C.-H.; PAN-CHYR YANG
臺大學術典藏	2020-12-02T02:34:18Z	Correlation of F-18 fluorodeoxyglucose-positron emission tomography maximal standardized uptake value and EGFR mutations in advanced lung adenocarcinoma	Huang C.-T.;Yen R.-F.;Cheng M.-F.;Hsu Y.-C.;Wei P.-F.;Tsai Y.-J.;Tsai M.-F.;Shih J.-Y.;Yang C.-H.;Pan-Chyr Yang; Huang C.-T.; Yen R.-F.; Cheng M.-F.; Hsu Y.-C.; Wei P.-F.; Tsai Y.-J.; Tsai M.-F.; Shih J.-Y.; Yang C.-H.; PAN-CHYR YANG

顯示項目 581-605 / 1273 (共51頁)
<< < 19 20 21 22 23 24 25 26 27 28 > >>
每頁顯示[10|25|50]項目

	English \| 正體中文 \| 简体中文 \| 總筆數 :2856565
	造訪人次 : 53427365 線上人數 : 698 教育部委託研究計畫計畫執行:國立臺灣大學圖書館